In vitro activity of a new quinoline derivative, ER-2, against clinical isolates of Mycoplasma pneumoniae and Mycoplasma hominis.
作者信息
Rao Shilpakala Sainath, Raghunathan Raghavachari, Ekambaram Ramesh, Raghunathan Malathi
出版信息
Antimicrob Agents Chemother. 2009 Dec;53(12):5317-8. doi: 10.1128/AAC.00746-09. Epub 2009 Sep 8.
Abstract
摘要
相似文献
1
In vitro activity of a new quinoline derivative, ER-2, against clinical isolates of Mycoplasma pneumoniae and Mycoplasma hominis.
Antimicrob Agents Chemother. 2009 Dec;53(12):5317-8. doi: 10.1128/AAC.00746-09. Epub 2009 Sep 8.
2
In vitro activity of the new quinolone derivative RD-3 against clinical isolates of Mycoplasma pneumoniae and Mycoplasma hominis.
J Antimicrob Chemother. 2009 Dec;64(6):1336-8. doi: 10.1093/jac/dkp375. Epub 2009 Oct 21.
3
Activities of the Benzoquinolizine Fluoroquinolone Levonadifloxacin (WCK 771) and Other Antimicrobial Agents against Mycoplasmas and Ureaplasmas in Humans, Including Isolates with Defined Resistance Mechanisms.
Antimicrob Agents Chemother. 2018 Oct 24;62(11). doi: 10.1128/AAC.01348-18. Print 2018 Nov.
4
In-vitro susceptibilities of Mycoplasma pneumoniae, Mycoplasma hominis and Ureaplasma urealyticum to clinafloxacin, PD 131628, ciprofloxacin and comparator drugs.
J Antimicrob Chemother. 1997 Aug;40(2):308-9. doi: 10.1093/jac/40.2.308.
5
Comparative in vitro activities of investigational peptide deformylase inhibitor NVP LBM-415 and other agents against human mycoplasmas and ureaplasmas.
Antimicrob Agents Chemother. 2005 Jun;49(6):2541-2. doi: 10.1128/AAC.49.6.2541-2542.2005.
6
Susceptibilities of Mycoplasma hominis, M. pneumoniae, and Ureaplasma urealyticum to GAR-936, dalfopristin, dirithromycin, evernimicin, gatifloxacin, linezolid, moxifloxacin, quinupristin-dalfopristin, and telithromycin compared to their susceptibilities to reference macrolides, tetracyclines, and quinolones.
Antimicrob Agents Chemother. 2001 Sep;45(9):2604-8. doi: 10.1128/AAC.45.9.2604-2608.2001.
7
In Vitro Activities of Omadacycline (PTK 0796) and Other Antimicrobial Agents against Human Mycoplasmas and Ureaplasmas.
Antimicrob Agents Chemother. 2016 Nov 21;60(12):7502-7504. doi: 10.1128/AAC.01734-16. Print 2016 Dec.
8
In vitro development of resistance to six and four fluoroquinolones in Mycoplasma pneumoniae and Mycoplasma hominis, respectively.
Antimicrob Agents Chemother. 2005 Mar;49(3):1190-3. doi: 10.1128/AAC.49.3.1190-1193.2005.
9
In vitro activity of midecamycin diacetate against Mycoplasma pneumoniae and Chlamydia pneumoniae.
J Antimicrob Chemother. 2001 Feb;47(2):240-1. doi: 10.1093/jac/47.2.240.
10
Bactericidal activity of levofloxacin against Mycoplasma pneumoniae.
J Antimicrob Chemother. 2003 Sep;52(3):527-8. doi: 10.1093/jac/dkg365. Epub 2003 Jul 29.
本文引用的文献
1
Synthesis and antibacterial property of quinolines with potent DNA gyrase activity.
Bioorg Med Chem. 2009 Jan 15;17(2):660-6. doi: 10.1016/j.bmc.2008.11.058. Epub 2008 Dec 3.
2
Mycoplasma pneumoniae and its role as a human pathogen.
Clin Microbiol Rev. 2004 Oct;17(4):697-728, table of contents. doi: 10.1128/CMR.17.4.697-728.2004.
3
Susceptibilities of Mycoplasma hominis, Mycoplasma pneumoniae, and Ureaplasma urealyticum to a new quinolone, OPC 17116.
Antimicrob Agents Chemother. 1993 Aug;37(8):1726-7. doi: 10.1128/AAC.37.8.1726.
4
Structure-activity and structure-side-effect relationships for the quinolone antibacterials.
J Antimicrob Chemother. 1994 Apr;33(4):685-706. doi: 10.1093/jac/33.4.685.
Zotero 插件